The Global Research-grade Proteins Market size is expected to reach $2.5 Billion by 2030, rising at a market growth of 15.2% CAGR during the forecast period.
Immune checkpoint proteins, also known as immune checkpoint molecules or inhibitors, are critical regulators of the immune system's response to antigens, including pathogens and cancer cells. Consequently, the Immune checkpoint proteins segment registered $109.9 million revenue of the market in 2022. These proteins balance the immune system's ability to attack foreign invaders while avoiding excessive damage to healthy tissues. Dysregulation of immune checkpoint proteins can lead to immune system dysfunction and contribute to various diseases, including cancer and autoimmune disorders. These therapies have shown remarkable success in treating various types of cancer and are a promising area of research in oncology. Some of the factors Impacting on the market are use of these proteins in industrial applications, growing research activities for drug discovery and precision medicine and regulatory and safety concerns regarding protein production.
The versatility of research-grade proteins is a positive aspect. They serve as essential tools in various industrial applications, ranging from food quality control to bioprocess optimization. Their adaptability to different contexts and their role in supporting quality assurance, process efficiency, and product innovation make them invaluable in diverse industrial settings. Proteins play a critical role in ensuring the quality and safety of food products, and as consumer demands for better food quality increase, so does the need for high-quality research-grade proteins for testing and analysis. These drives sustained demand for these proteins within the food and beverage industry. These are crucial for identifying and validating potential drug targets. Researchers use these proteins to study the biological functions of specific proteins and determine if they are suitable targets for drug development. In drug discovery, high-throughput screening assays are used to test thousands of compounds for their potential as drug candidates. These are employed in these assays to assess the compounds' interactions with target proteins. After identifying initial hits in drug screening, researchers use these proteins to optimize lead compounds and enhance their binding affinity and selectivity for the target.
However, Regulatory agencies, like the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA), have established strict guidelines and requirements for producing, quality control, and characterizing proteins, including research-grade proteins. Meeting regulatory standards can be complex and resource-intensive, requiring adherence to Good Manufacturing Practices (GMP) and Good Laboratory Practices (GLP) standards. Ensuring the purity and quality of these proteins is essential to prevent contamination and ensure reliable research results. Contaminants such as endotoxins, host cell proteins, and adventitious agents must be monitored rigorously. Accurate record-keeping and data integrity are essential for regulatory compliance and quality control. Ensuring the integrity of research data is a critical consideration. These challenges may hamper the market’s growth.
Moreover, the COVID-19 had a moderate impact on the market. The COVID-19 pandemic disrupted supply chains worldwide due to lockdowns, travel restrictions, and labor shortages. This disruption affected the production and distribution of research-grade proteins, potentially leading to delays in product availability. Research institutions and biotechnology companies redirected their resources and efforts toward COVID-19-related research and vaccine development. This shift in research priorities temporarily reduced demand for other research-grade proteins in non-COVID research areas. Economic challenges and uncertainties resulting from the pandemic influenced research budgets and funding availability. Collaborative research efforts and partnerships between academia, industry, and government agencies influenced the demand and use of research-grade proteins. Therefore, the market will grow significantly after the pandemic.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Thermo Fisher Scientific, Inc., Abcam Plc, Miltenyi Biotech B.V. & Co. KG, Genscript Biotech Corporation, Bio-Techne Corporation, Proteintech Group, Inc., AcroBiosystems INC., Sino Biologicals, Inc. and ProSpec-Tany TechnoGene Ltd. and New England Biolabs, Inc.
Immune checkpoint proteins, also known as immune checkpoint molecules or inhibitors, are critical regulators of the immune system's response to antigens, including pathogens and cancer cells. Consequently, the Immune checkpoint proteins segment registered $109.9 million revenue of the market in 2022. These proteins balance the immune system's ability to attack foreign invaders while avoiding excessive damage to healthy tissues. Dysregulation of immune checkpoint proteins can lead to immune system dysfunction and contribute to various diseases, including cancer and autoimmune disorders. These therapies have shown remarkable success in treating various types of cancer and are a promising area of research in oncology. Some of the factors Impacting on the market are use of these proteins in industrial applications, growing research activities for drug discovery and precision medicine and regulatory and safety concerns regarding protein production.
The versatility of research-grade proteins is a positive aspect. They serve as essential tools in various industrial applications, ranging from food quality control to bioprocess optimization. Their adaptability to different contexts and their role in supporting quality assurance, process efficiency, and product innovation make them invaluable in diverse industrial settings. Proteins play a critical role in ensuring the quality and safety of food products, and as consumer demands for better food quality increase, so does the need for high-quality research-grade proteins for testing and analysis. These drives sustained demand for these proteins within the food and beverage industry. These are crucial for identifying and validating potential drug targets. Researchers use these proteins to study the biological functions of specific proteins and determine if they are suitable targets for drug development. In drug discovery, high-throughput screening assays are used to test thousands of compounds for their potential as drug candidates. These are employed in these assays to assess the compounds' interactions with target proteins. After identifying initial hits in drug screening, researchers use these proteins to optimize lead compounds and enhance their binding affinity and selectivity for the target.
However, Regulatory agencies, like the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA), have established strict guidelines and requirements for producing, quality control, and characterizing proteins, including research-grade proteins. Meeting regulatory standards can be complex and resource-intensive, requiring adherence to Good Manufacturing Practices (GMP) and Good Laboratory Practices (GLP) standards. Ensuring the purity and quality of these proteins is essential to prevent contamination and ensure reliable research results. Contaminants such as endotoxins, host cell proteins, and adventitious agents must be monitored rigorously. Accurate record-keeping and data integrity are essential for regulatory compliance and quality control. Ensuring the integrity of research data is a critical consideration. These challenges may hamper the market’s growth.
Moreover, the COVID-19 had a moderate impact on the market. The COVID-19 pandemic disrupted supply chains worldwide due to lockdowns, travel restrictions, and labor shortages. This disruption affected the production and distribution of research-grade proteins, potentially leading to delays in product availability. Research institutions and biotechnology companies redirected their resources and efforts toward COVID-19-related research and vaccine development. This shift in research priorities temporarily reduced demand for other research-grade proteins in non-COVID research areas. Economic challenges and uncertainties resulting from the pandemic influenced research budgets and funding availability. Collaborative research efforts and partnerships between academia, industry, and government agencies influenced the demand and use of research-grade proteins. Therefore, the market will grow significantly after the pandemic.
Product Outlook
On the basis of product, the market is segmented into cytokines & growth factors, antibodies, immune checkpoint proteins, virus antigens, enzymes, recombinant regulatory proteins, hormones, and others. The enzymes segment projected a remarkable revenue share in the market in 2022. Enzymes are biological molecules that perform as catalysts in living organisms. They play a fundamental role in speeding up chemical reactions, allowing them to occur at a rate compatible with life. Enzymes are essential for functioning in various biological processes, including metabolism, digestion, cellular respiration, and DNA replication.
Host Cell Outlook
Based on host cell, the market is fragmented into mammalian cells, bacterial cells, fungi & yeast, insect cells, and others. In 2022, the mammalian cells segment witnessed the largest revenue share in the market. Due to the similar biological makeup to human cells, mammalian cells are widely used in the production of biopharmaceuticals, including monoclonal antibodies, vaccines, therapeutic proteins, and growth factors, among others. In a clinical study conducted by researchers of Karolinska Institute and Karolinska University Hospital and published in March 2023, a possible basic mechanism for the enhancement of cardiac pump function using ghrelin was identified by scientists by studying isolated mouse heart cells in the laboratory.End User Outlook
By end-use, the market is classified into pharmaceutical & biotechnology companies, academic & research institute, and others. In 2022, the pharmaceutical & biotechnology companies segment generated the highest revenue share in the market. The growing drug discoveries & development, rising need for personalized medicines, and growing number of clinical trials are expected to drive the segment's expansion over the forecast period. Moreover, continuous investments by governments to support rising R & D activities are further expected to accelerate the segment's growth.Regional Outlook
Region-wise, the research-grade proteins market is analysed across North America, Europe, Asia Pacific, and LAMEA. The Asia Pacific region garnered a significant revenue share in the market in 2022. Due to the increasing awareness of novel technologies, developing healthcare infrastructure, and surging demand for advanced diagnostics & efficient therapeutic solutions, the market is expected to have a lucrative growth rate. Furthermore, regional emerging economies are establishing research facilities and infrastructure for the biotechnology sector. With the rising number of clinical studies on cancer research and drug development, the Asia Pacific market is anticipated to grow over the years.The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Thermo Fisher Scientific, Inc., Abcam Plc, Miltenyi Biotech B.V. & Co. KG, Genscript Biotech Corporation, Bio-Techne Corporation, Proteintech Group, Inc., AcroBiosystems INC., Sino Biologicals, Inc. and ProSpec-Tany TechnoGene Ltd. and New England Biolabs, Inc.
Strategies deployed in the Market
- Jan-2022: Thermo Fisher Scientific Inc. completed the acquisition of PeproTech, Inc, a producer of high-quality recombinant cytokines and growth factors supports life science research. Through this acquisition Thermo fisher aimed to better serve its pharma and biotech customers by adding new capabilities with the help of PeproTech and leveraging its commercial reach which will allow them to generate better financial results.
- Aug-2023: Genscript Biotech Corporation Joined hands with T-Maximum Biotech, a biotechnology company specializing in cell therapies. With this agreement Genscript aims to provide various CRISPR reagents which will support the development of T-Maximum universal CAR-T products from development phase to commercialization along with that it also supports T-Maximum strategic development plan to progress multiple products to stage 2 trials and deliver the products to the market within next 5 years.
- Mar-2023: GenScript biotech Corporation entered into an agreement with personen-Anke Cellular Therapeutics Co., Ltd., a biotech company focusing on developing leading-edge cellular therapeutics. Through this agreement Genscript aimed to develop cell isolation products which will promote the development of China’s cell therapy industry which will benefit more patients.
- Mar-2022: Sino Biological, Inc. formed a partnership with Ainnocence, Inc., a company that provides generative AI based small-and large-molecule design systems that dramatically lower the costs and risk of drug discovery. Through this partnership Sino Biologicals aimed to use Ainnocence artificial intelligence-based prediction technology for its existing antibody development CRO service offering which will save customers development time and ensuring antibody-antigen binding affinities that meet the strict demands.
Scope of the Study
Market Segments Covered in the Report:
By Host Cell- Mammalian Cells
- Bacterial Cells
- Yeast & Fungi
- Insect Cells
- Others
- Cytokines & Growth Factors
- Immune Checkpoint Proteins
- Enzymes
- Hormones
- Antibodies
- Virus Antigens
- Recombinant Regulatory Proteins
- Others
- Pharmaceutical & Biotechnology Companies
- Academic & Research Institutes
- Others
- North America
- US
- Canada
- Mexico
- Rest of North America- Europe
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe- Asia Pacific
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific- LAMEA
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Key Market Players
List of Companies Profiled in the Report:
- Thermo Fisher Scientific, Inc.
- Abcam Plc
- Miltenyi Biotech B.V. & Co. KG
- Genscript Biotech Corporation
- Bio-Techne Corporation
- Proteintech Group, Inc.
- AcroBiosystems INC.
- Sino Biologicals, Inc.
- ProSpec-Tany TechnoGene Ltd.
- New England Biolabs, Inc.
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market at a Glance
Chapter 3. Market Overview
Chapter 5. Global Research-grade Proteins Market, by Host Cell
Chapter 6. Global Research-grade Proteins Market, by Product
Chapter 7. Global Research-grade Proteins Market, by End-use
Chapter 8. Global Research-grade Proteins Market, by Region
Chapter 9. Company Profiles
Companies Mentioned
- Thermo Fisher Scientific, Inc.
- Abcam Plc
- Miltenyi Biotech B.V. & Co. KG
- Genscript Biotech Corporation
- Bio-Techne Corporation
- Proteintech Group, Inc.
- AcroBiosystems INC.
- Sino Biologicals, Inc.
- ProSpec-Tany TechnoGene Ltd.
- New England Biolabs, Inc.
Methodology
LOADING...
